These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33417267)

  • 1. miR-218 contributes to drug resistance in multiple myeloma via targeting LRRC28.
    Chen H; Cao W; Chen J; Liu D; Zhou L; Du F; Zhu F
    J Cell Biochem; 2021 Apr; 122(3-4):305-314. PubMed ID: 33417267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
    Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
    Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
    [No Abstract]   [Full Text] [Related]  

  • 3. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
    Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
    Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
    Tang JX; Chen Q; Li Q; He YH; Xiao D
    Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
    Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
    BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
    Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
    Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
    Liu Y; Cheng P; Zhao W; Zhu L; Sui J; Dai Y; Lai Y
    Leuk Res; 2022 Mar; 114():106785. PubMed ID: 35074616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.
    Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y
    Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.
    Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J
    Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
    Che F; Ye X; Wang Y; Ma S; Wang X
    Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
    Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
    Zhong S; Li W; Chen Z; Xu J; Zhao J
    Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
    Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
    Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
    Xia L; Zhang D; Du R; Pan Y; Zhao L; Sun S; Hong L; Liu J; Fan D
    Int J Cancer; 2008 Jul; 123(2):372-379. PubMed ID: 18449891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
    Zhang L; Pan L; Xiang B; Zhu H; Wu Y; Chen M; Guan P; Zou X; Valencia CA; Dong B; Li J; Xie L; Ma H; Wang F; Dong T; Shuai X; Niu T; Liu T
    Oncotarget; 2016 May; 7(21):30876-91. PubMed ID: 27129167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
    Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
    Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.